Understanding how a drug works against a common parasitic infection.
Resolving the properties of schistosome TRPMPZQ, the target of the anthelmintic drug praziquantel
['FUNDING_R01'] · MEDICAL COLLEGE OF WISCONSIN · NIH-11164229
This study is looking at how the drug praziquantel works to treat schistosomiasis, a disease that affects millions of people, by focusing on a specific part of the parasite that the drug targets, with the goal of finding better treatments in the future.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MEDICAL COLLEGE OF WISCONSIN (nih funded) |
| Locations | 1 site (MILWAUKEE, UNITED STATES) |
| Trial ID | NIH-11164229 on ClinicalTrials.gov |
What this research studies
This research focuses on schistosomiasis, a parasitic infection affecting over 250 million people globally, and aims to uncover the molecular target of the drug praziquantel (PZQ), which is currently the only treatment available. The researchers have identified a specific ion channel in the parasite, known as TRPMPZQ, that is crucial for the drug's effectiveness. By understanding how this target works, the study hopes to pave the way for the development of improved therapies and better management of drug resistance. This research could lead to more effective treatments for those suffering from schistosomiasis.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with schistosomiasis, particularly those who may not respond well to current treatments.
Not a fit: Patients who do not have schistosomiasis or those who are not affected by parasitic infections may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new and more effective treatments for schistosomiasis, improving health outcomes for millions of affected individuals.
How similar studies have performed: Previous research has successfully identified drug targets in other parasitic infections, suggesting that this approach has the potential for significant breakthroughs.
Where this research is happening
MILWAUKEE, UNITED STATES
- MEDICAL COLLEGE OF WISCONSIN — MILWAUKEE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MARCHANT, JONATHAN S — MEDICAL COLLEGE OF WISCONSIN
- Study coordinator: MARCHANT, JONATHAN S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.